<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03436017</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI17/METHADA</org_study_id>
    <nct_id>NCT03436017</nct_id>
  </id_info>
  <brief_title>Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children</brief_title>
  <acronym>METHADA</acronym>
  <official_title>Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attention-deficit with or without hyperactivity disorder (ADHD) is a real health public&#xD;
      concern. No easy-use diagnosis tool are available. Metabolomic approaches has brought very&#xD;
      usefull data in others neurological diseases like amyotrophic lateral sclerosis or autism&#xD;
      spectrum disorder, as we had shown in previous studies. Targeting on neurotransmitter&#xD;
      pathways involving in ADHD, metabolomic screening could help to enhance our diagnosis power&#xD;
      to better help numerus of children. We propose to study the phenylalanine and the tyrosine&#xD;
      pathways with a multimodal metabolomic approach, in easy-available biological fluid (blood&#xD;
      and urine), in child or adolescent suspected of ADHD. Our objectives are: 1- to determine a&#xD;
      specific metabolomic signature of ADHD 2- to compare the diagnostic value of this metabolomic&#xD;
      signature with the reference methodology for ADHD diagnosis, as now practiced in our&#xD;
      reference center for learning troubles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Actual">November 12, 2019</completion_date>
  <primary_completion_date type="Actual">November 12, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD metabolomic's signature of blood</measure>
    <time_frame>At baseline</time_frame>
    <description>Detection of metabolites (phenylalanine or catécholamines) in the blood of patients with ADHD at levels significantly different from baseline levels in the general population and rates found in patients with attention deficit and / or hyperactivity disorders but that multidisciplinary assessment excludes the diagnosis of ADHD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADHD metabolomic's signature of urine</measure>
    <time_frame>At baseline</time_frame>
    <description>Detection of metabolites (phenylalanine or catécholamines) in the urine of patients with ADHD at levels significantly different from baseline levels in the general population and rates found in patients with attention deficit and / or hyperactivity disorders but that multidisciplinary assessment excludes the diagnosis of ADHD.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">89</enrollment>
  <condition>Adhd</condition>
  <arm_group>
    <arm_group_label>ADHD</arm_group_label>
    <description>Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non ADHD</arm_group_label>
    <description>Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.&#xD;
The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metabolomic approach</intervention_name>
    <description>Biological samples (blood and urine) for a multimodal metabolomic approach</description>
    <arm_group_label>ADHD</arm_group_label>
    <arm_group_label>non ADHD</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples Urinary samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Child or adolescent with symptoms of attention disorders and / or hyperactivity, aged from&#xD;
        6 to 15 years old, and consulting in current care in our university hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Child or adolescent with symptoms of attention disorders and / or hyperactivity&#xD;
&#xD;
          -  aged from 6 to 15 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure or refusal of all or part of the multidisciplinary evaluation (medical and /&#xD;
             or neuropsychological assessments and / or biological assessments)&#xD;
&#xD;
          -  Identification of an intercurrent condition likely to have an impact on metabolomic&#xD;
             analyzes (acute infection, fever, etc.)&#xD;
&#xD;
          -  Parents or legal guardians opposed to data processing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre CASTELNAU, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adhd</keyword>
  <keyword>metabolomics</keyword>
  <keyword>child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

